Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Garetosmab (Primary) ; Garetosmab (Primary)
- Indications Fibrodysplasia ossificans progressiva; Osteoporosis
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
- 18 Jun 2020 Results published in the Journal of Clinical Pharmacology
- 16 Feb 2017 Status changed from active, no longer recruiting to completed.
- 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.